Rifaximin is a gut-specific human pregnane X receptor activator

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 391-398

  Ma, Xiaochao ^a   Shah, Yatrik M ^a   Guo, Grace L ^b   Wang, Ting ^a   Krausz, Kristopher W ^a   Idle, Jeffrey R ^c   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ANDROSTANE DERIVATIVE; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; MIDAZOLAM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; RIFAMPICIN; RIFAXIMIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DETOXIFICATION; DRUG ACTIVATION; GASTROINTESTINAL DISEASE; GENE CONTROL; GENE INDUCTION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; THERAPY EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HUMANS; INTESTINES; MALE; MICE; MIDAZOLAM; RECEPTORS, STEROID; RIFAMPIN; RIFAMYCINS;

EID: 34250705295     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.121913     Document Type: Article

References (40)

1. Abdelrazeq AS, Kelly SM, Lund JN, and Leveson SH (2005) Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 7:182-186.
2. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95:12208-12213.
3. Carnahan VE and Redinbo MR (2005) Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 6:357-367.
4. 3H-rifaximin to rats. Chemioterapia 3:373-377.
5. Descombe JJ, Dubourg D, Picard M, and Palazzini E (1994) Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 14:51-56.
6. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, and Corazza GR (2000) Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 14:1001-1008.
7. Doherty MM and Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism. Clin Pharmacokinet 41:235-253.
8. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O'Donoghue D, O'Sullivan M, et al. (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341-348; quiz 592.
9. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, and Campieri M (2006) Antimicrobials in the management of inflammatory bowel disease. Digestion 73 (Suppl 1):77-85.
10. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, and Campieri M (1999) Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 13:713-718.
11. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, and Gonzalez FJ (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-558.
12. Guo GL, Staudinger J, Ogura K, and Klaassen CD (2002) Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16α-carbonitrile is via interaction with pregnane X receptor. Mol Pharmacol 61:832-839.
13. Guslandi M, Petrone MC, and Testoni PA (2006) Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 12:335.
14. Jiang ZD, Ke S, Palazzini E, Riopel L, and Dupont H (2000) In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 44:2205-2206.
15. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, and Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915.
16. Kliewer SA (2003) The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 133:2444S-2447S.
17. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
18. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, and Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774.
19. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, and Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127:26-40.
20. Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M, and Frieri G (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55-62.
21. Laustsen G and Wimmett L (2005) 2004 Drug approval highlights: FDA update. Nurse Pract 30:14-29; quiz 29-31.
22. Loguercio C, Federico A, De Girolamo V, Ferrieri A, and Del Vecchio Blanco C (2003) Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 49:53-62.
23. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, and Gonzalez FJ (2007) The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194-200.
24. Maher JM, Cheng X, Slitt AL, Dieter MZ, and Klaassen CD (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33:956-962.
25. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodriguez-Martinez D, Fernandez-Rodriguez C, Coll I, et al. (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38:51-58.
26. Miki Y, Suzuki T, Tazawa C, Blumberg B, and Sasano H (2005) Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231:75-85.
27. Papi C, Koch M, and Capurso L (2005) Management of diverticular disease: is there room for rifaximin. Chemotherapy 51 (Suppl 1):110-114.
28. Pistoia MA, Lombardi L, Rossi M, Vittorini C, Cavaliere GF, and Pistoia F (2004) Does rifaximin prevent complications of diverticular disease? A retrospective study. Eur Rev Med Pharmacol Sci 8:283-287.
29. Rosenfeld JM, Vargas R, Jr., Xie W, and Evans RM (2003) Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282.
30. Saini SP, Mu Y, Gong H, Toma D, Uppal H, Ren S, Li S, Poloyac SM, and Xie W (2005) Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology 41:497-505.
31. Scarpignato C and Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 (Suppl 1):36-66.
32. Shafran I and Johnson LK (2005) An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 21:1165-1169.
33. Shah YM, Ma X, Morimura K, Kim I, and Gonzalez FJ (2007) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-{kappa}B target gene expression. Am J Physiol 292:G1114-G1122.
34. Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, and Evans RM (2005) Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A 102:2198-2203.
35. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369-3374.
36. Swales K, Kakizaki S, Yamamoto Y, Inoue K, Kobayashi K, and Negishi M (2005) Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells. J Biol Chem 280:3458-3466.
37. Trapnell CB, Connolly M, Pentikis H, Forbes WP, and Bettenhausen DK (2007) Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 41:222-228.
38. Venturini AP (1983) Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 29:1-3.
39. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, and Trauner M (2005) CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42:420-430.
40. Yueh MF, Kawahara M, and Raucy J (2005) High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 33:38-48.